Prof. Michel Revel, Chief Scientific Officer of NewcelX, added, "Prof. Ben-Hur's involvement with NewcelX brings deep clinical expertise and a shared commitment to advancing innovative cell therapies that address the root causes of neurodegenerative disease." Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX, stated, "We are honored that Prof. Ben-Hur will join us in NewcelX. His decision reflects confidence in our science and our mission to build a global biotechnology company deliveri ...

Proven technology executive will oversee enterprise architecture and strategy as Company expands globallyVANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the hiring of Brian Ellis as the Company’s Chief Information and Technology Officer (CITO). In this newly created leadership position for the Company, Mr. Ellis will oversee Village Farms’ enterprise architecture and IT strategy as the Company c ...

SHENZHEN, China, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025 on November 13, 2025 before market open. The earnings press release will be available on the Company's investor relations page at http://ir.xunlei.com. Conference Call Xunlei's management will host a confer ...

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced its financial results ...

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe The NEO-CYT Study will evaluate MDNA11 as a neoadjuvant immunotherapy in earlier-stage melanoma patients whose immune systems are more amenable to immunotherapy and may be more likely to benefit from MDNA11 treatment Based on deep and dur ...

STAFFORD, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), a global leader in advanced battery technologies, will issue a press release reporting its consolidated financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Following the earnings press release, Microvast management will host a webcast and earnings conference call at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the business resu ...

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide in Combin ...

Visual messaging app Snapchat's owner Snap saw its shares soaring by more than 20% during pre-market trading on Thursday after its third quarter earnings results beat Wall Street estimates, while the ... ...

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology compa ...

Strong Revenues and Adjusted EBITDA growth in Experiential Services partially offsetting softness in Branded Services Generated $98 million in adjusted unlevered free cash flow and ended the quarter with strong cash position of $201 million Rapidly responded to robust demand in high-volume labor businesses generating strong incremental margin Reaffirm Revenue and modestly lower Adjusted EBITDA outlook due to impact of divestiture and macro environment ST. LOUIS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Advantage ...